🎧 ▶️ Press the play button below to listen in English.
Introduction
If you follow health trends, you’ve probably noticed that cannabis is increasingly being talked about as a treatment for anxiety, depression, PTSD, insomnia, and even addiction.
Medical cannabis programs are expanding rapidly across the United States, Canada, Australia, and parts of Europe. In fact, mental health conditions now make up six of the top ten reasons people are prescribed medical cannabis in Australia.
But here’s the uncomfortable question: Does the scientific evidence actually support this practice?
A massive new study published in The Lancet Psychiatry in April 2026 set out to answer exactly that.
Researchers conducted the largest and most comprehensive review ever assembled on this topic—analyzing 54 randomized controlled trials involving nearly 2,500 participants.
This is the gold standard of medical research, in which real treatments are compared against placebos under carefully controlled conditions.
The findings might surprise you.
What the Researchers Did
The team, led by Jack Wilson and Dr. Emily Stockings, scoured every major medical database for studies published between 1980 and 2025. They were looking specifically for trials where cannabis-based medicines were used as the primary treatment for a mental health condition or substance use disorder—not as a side treatment for something else like chronic pain.
They examined outcomes for conditions including anxiety, depression, PTSD, schizophrenia, bipolar disorder, ADHD, OCD, anorexia, insomnia, Tourette’s syndrome, autism spectrum disorder, and various addictions.
Then came the hard part: they graded the quality of every piece of evidence using a rigorous system called GRADE, which tells us how confident we can really be in the results.
The Good News: Where Cannabis Showed Promise
Let’s start with what actually worked. A few bright spots emerged from the analysis.
Cannabis Use Disorder
Ironically, cannabis-based medicines—specifically those combining THC and CBD (like the pharmaceutical product nabiximols)—helped people reduce their use of non-medical cannabis. People experienced fewer withdrawal symptoms and cut down their weekly cannabis consumption. This makes intuitive sense: it’s essentially a replacement therapy, similar to how nicotine patches help people quit smoking.
Tic Disorders and Tourette’s Syndrome
People receiving cannabinoid treatment, particularly the THC-CBD combination, showed meaningful reductions in tic severity. For a condition with limited effective medication options, this is encouraging.
Insomnia
Here’s where the evidence was strongest. People with insomnia who took cannabinoids slept longer—about half a standard deviation more than placebo groups—when sleep was measured objectively with electronic devices.
Sleep diaries kept by participants confirmed this finding. The quality of evidence for device-measured sleep improvement was rated “moderate,” which is actually quite good by medical research standards.
Autism Spectrum Disorder
Two studies found reductions in autistic traits among participants taking cannabinoids. However—and this is important—both studies had significant methodological problems, and the overall certainty of this evidence was rated “very low.”
The Not-So-Good News: Where Cannabis Didn’t Help
Now for the findings that may disappoint many people.
Anxiety Disorders
Despite being one of the most common reasons people use medical cannabis, the review found no significant benefit for anxiety symptoms across six studies involving 352 participants.
The researchers noted that the evidence was of very low quality and that any perceived benefits in real-world settings might be due to placebo effects.
PTSD
Three studies examined PTSD, and none showed meaningful improvement in core PTSD symptoms. This is striking given that PTSD is frequently cited as a qualifying condition for medical cannabis programs.
Depression
Here’s a shocking finding: There were zero randomized controlled trials examining cannabis for depression. Not one.
Depression is arguably the most common mental health condition worldwide, and one of the top reasons people report using cannabis, yet the gold-standard research simply doesn’t exist.
Psychotic Disorders (Schizophrenia)
Eight studies tested cannabinoids (mostly CBD) for schizophrenia and related conditions. There was no significant improvement in any symptom category—positive symptoms, negative symptoms, or general functioning.
Opioid Use Disorder
Four studies found no benefit for reducing opioid withdrawal symptoms or cravings. This is particularly important given ongoing discussions about using cannabis to address the opioid crisis.
Cocaine Use Disorder
This is where the news gets actively concerning. People taking cannabinoids for cocaine addiction actually experienced increased cocaine cravings compared to those taking placebo. The treatment appeared to make the problem worse, not better.
ADHD, Bipolar Disorder, OCD, Anorexia, and Tobacco Addiction
For all these conditions, there was either no benefit shown or so little data that no meaningful conclusions could be drawn.
The Safety Picture: What Are the Risks?
The researchers also analyzed adverse events across all 54 studies. Here’s what they found:
Common Side Effects
People taking cannabinoids were significantly more likely to experience side effects than those taking a placebo. The “number needed to treat to harm” (NNTH) was 7, meaning that for every seven people treated with cannabinoids, one additional person will experience an adverse event compared to placebo. The most common complaints included dry mouth, nausea, diarrhea, and dizziness.
Serious Adverse Events
Encouragingly, there was no increased risk of serious adverse events (like psychotic episodes or hospitalizations) among cannabinoid users compared to placebo groups. Study withdrawal rates were also similar between groups.
Important Caveat
The researchers emphasize that most of the included studies used pharmaceutical-grade cannabinoids with known doses and purity.
The unregulated, high-THC products commonly available in dispensaries might carry different—and potentially higher—risks that wouldn’t be captured in these controlled trials.
The Elephant in the Room: Quality of Evidence
Perhaps the most important finding isn’t about any specific condition—it’s about the overall state of the science.
Of the 54 studies analyzed:
- 24 studies (44%) were rated as having a high risk of bias
- 20 studies (37%) raised some concerns about bias
- Only 10 studies (18%) were considered low risk of bias
The GRADE assessments (which rate our confidence in the evidence) were sobering. For almost every outcome examined, the certainty of evidence was rated “low” or “very low.”
What causes bias in these studies? The researchers flagged several issues:
- Industry funding and author conflicts of interest
- Small sample sizes (the median study had just 31 participants)
- Lack of transparent reporting according to pre-registered protocols
- Inconsistent measurement of outcomes
Why This Matters Right Now
We’re living through a remarkable period of cannabis policy liberalization. Medical cannabis programs now exist in dozens of countries and most U.S. states.
In Australia, over one million applications for medical cannabis have been approved. Surveys consistently show that mental health is among the top reasons people seek out these products.
Yet this review reveals a yawning gap between public perception and scientific evidence. The authors put it bluntly:
“Given the scarcity of evidence, the routine use of cannabinoids for the treatment of mental disorders and Substance Use Disorders is currently rarely justified.”
This doesn’t mean cannabis is useless for mental health. It means we simply don’t have good enough evidence to recommend it as a standard treatment.
And there’s a real risk that people might delay or replace proven effective therapies—like cognitive behavioral therapy or established medications—with cannabis products of unknown benefit.
What Needs to Happen Next
The researchers outline a clear path forward:
Better Studies
We need larger trials with more diverse participants, transparent reporting of all outcomes, and independence from industry influence. The median study size of 31 participants is simply too small to draw reliable conclusions.
Targeted Research
The promising signals for insomnia, Tourette’s syndrome, and cannabis use disorder deserve follow-up with higher-quality trials. The complete absence of depression studies is a glaring gap that demands attention.
Regulatory Caution
The authors call for greater oversight of medical cannabis programs, including mandatory training for healthcare providers and accessible databases that clearly present the evidence (or lack thereof) for each condition.
Honest Public Messaging
People should understand that most cannabis products haven’t been rigorously tested for mental health applications, and that self-medicating with unregulated products carries unknown risks.
The Takeaway
Here’s what you should know:
• There is very little high-quality evidence that cannabis effectively treats most mental health conditions
• The best evidence exists for improving sleep time in insomnia (moderate certainty) and reducing cannabis use in people with cannabis use disorder (low certainty)
• Cannabis showed no benefit for anxiety, PTSD, depression, schizophrenia, bipolar disorder, ADHD, OCD, anorexia, or opioid addiction in available trials
• For cocaine addiction, cannabis may actually increase cravings—a potentially harmful effect
• There are zero randomized controlled trials examining cannabis for depression, despite it being one of the most common reasons people use it
• Side effects are common: 1 in 7 people will experience some adverse event compared to placebo
• Serious adverse events were not more common with cannabis than placebo, but most studies used pharmaceutical-grade products, not dispensary cannabis
• The overall quality of research in this field is poor, with nearly half of all studies showing high risk of bias
• Using cannabis for mental health might delay or replace treatments we know actually work
• More and better research is urgently needed before cannabis can be routinely recommended for mental health conditions
The bottom line? The science simply hasn’t caught up with the enthusiasm. If you’re considering cannabis for a mental health condition, have an honest conversation with a healthcare provider about what the evidence actually shows—and what it doesn’t show.
The most responsible approach is to view cannabis not as a proven treatment, but as an experimental option in an area where we still have far more questions than answers.
Don’t Get Sick!
About Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.
Related:
- How Marijuana Harms Your Mind And Body: Evidence-Based Risks
- Cut Alcohol Now Or Risk Deadly Pancreatic Cancer Later
- New Research Ends The Myth Of Healthy Alcohol Drinking
- Alcohol And Your Body: The Truth You Need To Know!
- Reliable Studies Agree: An Alcohol A Day Shrinks The Brain
- Alcohol And Heart Disease Risk: New Evidence Shows One Drink Is Too Many
- Harvard: Light alcohol intake increases cardiac risks
- Alcohol Abuse, Covid-19, and Lung Complications
- AUDIT C Screening: The Simple Test That Can Save Your Life!
- AIP and Mood Disorders – The Lipid Link to Depression and Bipolar Disorder
- Depression And Cardiovascular Risk: Calculate Your AIP Score Now
- Overcome Chronic Depression With Exercise, Healing Body And Mind
- How Grounding (Earthing) Can Reduce EMF Effects: A Simple Guide
- Five Best Breathing Techniques for Reducing Stress and Anxiety
- How Stress Depresses Immunity And Activates Hidden Diseases
- 25 Stress-Reduction Techniques
- Reclaim Your Calm: Stress Relief For Holidays Made Simple
- This Is What Really Happens When You Do Mindful Eating
- Mindful Eating: A Pathway to Lowering Postprandial Hyperglycemia
- The Awesome Benefits of Mindful Eating with Chopsticks
- Five Best Breathing Techniques for Reducing Stress and Anxiety
- Stress: The Hidden Trigger Behind Diabetes You Need To Know
- Fasting Vs. Depression: The Life-Changing Cure You Need Now
- Overcome Chronic Depression With Exercise, Healing Body And Mind
- Fasting Vs. Depression: The Life-Changing Cure You Need Now
- How Stress Depresses Immunity And Activates Hidden Diseases
References:
- Wilson J, Dobson O, Langcake A et al.The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis. The Lancet Psychiatry, 2026; 13, 304-315
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.